DETECT Nitazenes Act of 2025
- Bill Number
- S. 3093
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Science, Technology, Communications
- Status
- Introduced
- Latest Action
- 2025-11-03: Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
- Last Updated
- 2026-04-06T13:19:38Z
AI-Generated Summary
Purpose
The "Detection Equipment and Technology Evaluation to Counter the Threat of Nitazenes Act of 2025" (DETECT Nitazenes Act of 2025) aims to improve the U.S. government's ability to detect and address dangerous synthetic opioids, specifically nitazenes (a class of highly potent, lab-made drugs similar to fentanyl that can cause overdoses even in tiny amounts). It requires collaboration between the Department of Homeland Security (DHS) and the Drug Enforcement Administration (DEA) to develop better tools for identifying these substances at very low concentrations, building on existing efforts against drugs like fentanyl and xylazine (a veterinary sedative often mixed with opioids).
Key Provisions
- Short Title: Establishes the official name as the "DETECT Nitazenes Act of 2025."
- Core Requirement: Directs the DHS Science and Technology Directorate (S&T), which focuses on developing innovative security technologies, to partner with the DEA to enhance detection, identification, and disruption of illicit substances like nitazenes.
- Implementation: The bill amends an existing law to explicitly include nitazenes in federal priorities for drug detection technology.
Significant Changes to Existing Law
- Amends Section 302(15) of the Homeland Security Act of 2002 (which outlines the responsibilities of the DHS Under Secretary for Science and Technology).
- Specifically, it updates the list of targeted substances from "fentanyl and xylazine" to "fentanyl, xylazine, and nitazenes," ensuring nitazenes are now covered under DHS's mandate to develop detection capabilities in coordination with the DEA.
- This is a targeted expansion rather than a complete overhaul, integrating nitazenes into an already established framework for countering synthetic drug threats.
Potential Impacts
- On Government Agencies: Strengthens DHS and DEA's technological resources for border security, mail screening, and law enforcement operations, potentially leading to more effective interdiction of nitazenes entering the U.S.
- On Citizens: Could reduce overdose deaths by improving early detection of nitazenes in the drug supply, benefiting public health and communities hit hard by the opioid crisis (nitazenes are often undetectable without advanced tools and have caused rising fatalities).
- On International Relations: May enhance U.S. cooperation with international partners on drug trafficking, as nitazenes are produced abroad (e.g., in labs in China or Mexico), but it focuses domestically on detection rather than foreign policy changes.
Main Stakeholders Affected
- Government Agencies: Primary beneficiaries include the DHS Science and Technology Directorate (for tech development) and the DEA (for expertise on drug threats and enforcement).
- Law Enforcement and Public Health Officials: Local police, border patrol, and health departments gain from improved detection tools, aiding in seizures and harm reduction efforts.
- Citizens and Communities: Individuals at risk of opioid exposure, including users, first responders, and families affected by overdoses, stand to benefit from safer drug monitoring.
- Drug Traffickers: Adversely impacted, as enhanced detection could disrupt smuggling networks.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces existing federal authority under the Homeland Security Act without creating new powers; it promotes inter-agency collaboration, which is standard in U.S. drug policy. No challenges to due process or privacy rights are introduced, as it focuses on technology for illicit substances.
- Constitutional: Aligns with Congress's enumerated powers to regulate commerce and provide for national security (e.g., addressing interstate drug threats under the Commerce Clause).
- Political: Bipartisan support (introduced by senators from both parties) signals broad consensus on tackling the evolving opioid epidemic. It could influence future funding for DHS/DEA tech programs and highlight the need for ongoing updates to drug laws as new synthetics emerge, potentially setting a precedent for rapid legislative responses to public health crises.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (5)
Sen. McCormick, David [R-PA], Sen. Ricketts, Pete [R-NE], Sen. Gallego, Ruben [D-AZ], Sen. Slotkin, Elissa [D-MI], Sen. Shaheen, Jeanne [D-NH]
Recent Actions
- 2025-11-03: Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
- 2025-11-03: Introduced in Senate
Bill Versions
- Detection Equipment and Technology Evaluation to Counter the Threat of Nitazenes Act of 2025 — issued 2025-11-03 — PDF (2 pages)